Article
Gastroenterology & Hepatology
Yiqing Wang, Wenjie Ma, Raaj Mehta, Long H. Nguyen, Mingyang Song, David A. Drew, Francesco Asnicar, Curtis Huttenhower, Nicola Segata, Jonathan Wolf, Tim Spector, Sarah Berry, Kyle Staller, Andrew T. Chan
Summary: This study investigated the interaction between diet and gut microbiota in different subtypes of irritable bowel syndrome (IBS). The results showed that individuals with IBS-D consumed more healthy plant-based foods and fiber, while those with IBS-C tended to consume more unhealthy plant-based foods. Microbial diversity was lower in IBS-D patients, and specific variations in microbiota were found in different IBS subtypes.
Article
Gastroenterology & Hepatology
Sameer K. Berry, Rani Berry, David Recker, Jeffrey Botbyl, Lucy Pun, William D. Chey
Summary: Digital gut-directed hypnotherapy (GDH) treatment program can improve symptoms of IBS, including abdominal pain and stool problems. There was no significant difference in effectiveness between digital GDH and digital muscle relaxation (MR), but the GDH treatment group had more abdominal pain responders.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Maria J. Villanueva-Millan, Gabriela Leite, Jiajing Wang, Walter Morales, Gonzalo L. Parodi, Maya L. M. Pimentel, Gillian Barlow, Ruchi Mathur, Ali Rezaie, Maritza Sanchez, Sarah Ayyad, Daniel Cohrs, Christine Chang, Mohamad Rashid, Ava Hosseini, Alyson Fiorentino, Stacy Weitsman, Brennan Chuang, Bianca Chang, Nipaporn Pichetshote, Mark Pimentel
Summary: This study combines breath testing and stool microbiome sequencing to identify distinct gut microtypes associated with IBS-C and IBS-D subtypes. The findings suggest that methanogens such as M. smithii and H2S producers such as Fusobacterium and Desulfovibrio spp play a role in driving these subtypes.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Microbiology
Tarek Mazzawi
Summary: Research suggests that manipulating gut microbiota can improve symptoms of irritable bowel syndrome (IBS), with dietary management and other approaches showing promise in changing gut composition and alleviating IBS symptoms. However, more research is needed to identify the exact mixture of beneficial bacteria.
Article
Pharmacology & Pharmacy
Joost P. Algera, Hans Tornblom, Magnus Simren
Summary: Irritable bowel syndrome (IBS) is a common disorder of gut-brain interaction that affects 4% of the world's population. The pathophysiology of IBS is not fully understood, but recent studies have highlighted the importance of the gut microbiota and its potential role in alleviating gastrointestinal symptoms.
CURRENT OPINION IN PHARMACOLOGY
(2022)
Review
Immunology
Lin Xiao, Qin Liu, Mei Luo, Lishou Xiong
Summary: Research has identified the significant roles that microbiota-derived metabolites play in the development of IBS symptoms in patients, shedding light on the complex interplay between gut microbiota and IBS.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2021)
Article
Gastroenterology & Hepatology
Christopher J. Martoni, Shalini Srivastava, Anders Damholt, Gregory J. Leyer
Summary: This study found that Lactiplantibacillus plantarum (L. plantarum) Lpla33 (DSM34428) significantly improved symptoms in patients with IBS-D, reducing abdominal pain and bloating, and restoring normal bowel habits.
WORLD JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Lijun Mei, Jiaoli Zhou, Yimo Su, Kunhong Mao, Jing Wu, Caicai Zhu, Ling He, Ying Cui
Summary: The study found that Chinese IBS-D patients have reduced gut microbiota richness compared to healthy individuals, and their functional expression is abnormal, which may affect the inflammation and metabolism of the host.
BMC GASTROENTEROLOGY
(2021)
Article
Integrative & Complementary Medicine
Ya Zheng, Jessica Ching, Chung Wah Cheng, Wai Ching Lam, Kam Leung Chan, Xuan Zhang, Pui Yan Lam, Xing Yao Wu, Linda L. D. Zhong, Pei Hua Cao, Cho Wing Lo, Pui Kuan Cheong, Zhixiu Lin, Matthew Koh, Justin Wu, Zhao Xiang Bian
Summary: This study aims to evaluate the efficacy and safety of Chinese medicine JCM-16021 for IBS-D through a multi-center, randomized, double-blind, placebo-controlled clinical trial. The research hopes to provide more evidence to support Chinese medicine treatment for IBS-D.
Article
Gastroenterology & Hepatology
Qi Su, Hein M. Tun, Qin Liu, Yun Kit Yeoh, Joyce Wing Yan Mak, Francis K. L. Chan, Siew C. Ng
Summary: This study examined the association between gut microbiota and Irritable bowel syndrome (IBS) subtypes, and found that there are distinct differences in microbiota composition among different IBS subtypes. The microbial diversity is significantly reduced in IBS-D and IBS-U, but not in IBS-C. The study also identified microbial signatures associated with depression in IBS patients. Factors such as gender, age, and dietary patterns have significant effects on gut microbiota in different IBS subtypes. These findings emphasize the importance of personalized gut microbiome modulation approaches for optimal therapeutic effects in different subtypes of IBS.
Article
Gastroenterology & Hepatology
Aleksandra Kovaleva, Elena Poluektova, Roman Maslennikov, Anna Karchevskaya, Oleg Shifrin, Andrey Kiryukhin, Aleksandr Tertychnyy, Leonid Kovalev, Marina Kovaleva, Olga Lobanova, Anna Kudryavtseva, George Krasnov, Vladimir Ivashkin
Summary: This study found that patients with IDFO had increased biomarkers of intestinal barrier disorders at multiple levels. These disruptions were associated with the severity of clinical symptoms and changes in the gut microbiota.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Biochemistry & Molecular Biology
Qiang-Song Wang, Yi-Lun Wang, Wen-Yan Zhang, Kuang-Dai Li, Xiong-Fei Luo, Yuan-Lu Cui
Summary: IBS, especially IBS-D, affects approximately 9-20% of the global population, with traditional treatments often causing side effects. Natural medicines, such as puerarin, have gained attention for their beneficial effects in recent years. Puerarin has been found to reverse IBS-D symptoms by regulating gut microbiota and various physiological processes.
Article
Medicine, Research & Experimental
Haomeng Wu, Kai Zhan, Kehan Rao, Huan Zheng, Shumin Qin, Xudong Tang, Shaogang Huang
Summary: The effects of different rat models of diarrhea-predominant irritable bowel syndrome (IBS-D) on the brain-gut-microbiota (BGM) axis were evaluated in this study. The results showed that these models caused changes in brain gut peptides, cytokine levels, spinal cord neuronal activity, intestinal mucosal barrier function, and gut microbiota composition and structure.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Review
Gastroenterology & Hepatology
Brennan Spiegel
Summary: This article proposes a hypothesis, known as the gravity hypothesis, that seeks to explain the pathogenesis of irritable bowel syndrome (IBS) by relating it to the influence of gravity on human evolution. It suggests that ineffective gravity management systems may lead to the development of IBS. The article reviews the impact of gravity on human evolution, discusses the imperfect adaptation of Homo sapiens to gravity, and explores the consequences of gravity intolerance in relation to IBS. It also considers the diagnostic and therapeutic implications of this hypothesis and suggests further experiments to support or reject it.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Pharmacology & Pharmacy
Esther Colomier, Joost Algera, Chloe Melchior
Summary: Irritable bowel syndrome is a common disorder affecting the gut-brain axis, with four subtypes and a focus on pharmacological treatment for patients with IBS-D. The treatment remains challenging due to the heterogeneous patient population, lack of effective drugs, and multifactorial pathophysiology. Healthcare professionals can use a proposed algorithm for treating individual patients with IBS-D.
FRONTIERS IN PHARMACOLOGY
(2021)
